Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9789988 | 0.94 | L3MBTL1 (0.41) | L3MBTL1GRM5L3MBTL3SMN1; SMN2ALDH1A1 | |
| SCHEMBL2235706 | 0.88 | L3MBTL1 (0.44) | L3MBTL1GRM5L3MBTL3SMN1; SMN2ALDH1A1 | |
| SCHEMBL11454847 | 0.83 | ALDH1A1 (0.34) | L3MBTL1L3MBTL3ALDH1A1HPGDAPOBEC3G | |
| SCHEMBL27811174 | 0.81 | ALDH1A1 (0.33) | ALDH1A1HPGDAPOBEC3G | |
| SCHEMBL738007 | 0.79 | L3MBTL1 (0.40) | L3MBTL1GRM5L3MBTL3SMN1; SMN2ALDH1A1 | |
| SCHEMBL7008001 | 0.79 | — | — | |
| SCHEMBL3355983 | 0.77 | OPRL1 (0.33) | ALDH1A1HPGDAPOBEC3G | |
| SCHEMBL7369318 | 0.77 | CYP2D6 (0.31) | — | |
| SCHEMBL6370243 | 0.73 | L3MBTL1 (0.39) | L3MBTL1GRM5L3MBTL3SMN1; SMN2ALDH1A1 | |
| SCHEMBL736704 | 0.73 | L3MBTL1 (0.39) | L3MBTL1GRM5L3MBTL3SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970572-B | Photocurable composition | SEKISUI CHEMICAL CO LTD | 2014-01-29 | — | — | CN | disclosed |
| CN-100516049-C | Antiangiogenic agent N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles | YUNG SHIN PHARM IND CO LTD (CN) | 2009-07-22 | — | — | CN | disclosed |
| CN-1962640-A | Novel anti-angiogenic drug N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles | YUNG SHIN PHARM IND CO LTD (CN) | 2007-05-16 | — | — | CN | disclosed |
| EP-1259475-A4 | TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS | UNIV YALE (US) | 2004-08-18 | — | — | EP | disclosed |
| CN-1117077-C | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER (US) | 2003-08-06 | — | — | CN | disclosed |
| CN-1105706-C | Cyclic amidino formulations useful as nitric oxide synthase inhibitors | SEARLE & CO (US) | 2003-04-16 | — | — | CN | disclosed |
| EP-1259475-A1 | TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS | YALE UNIVERSITY (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6384282-B2 | CATALYST IS REACTION PRODUCT OF GROUP 8 METAL AND LIGAND | YALE UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| US-20020016509-A1 | Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds | YALE UNIVERSITY | 2002-02-07 | — | — | US | disclosed |
| WO-2001064620-A1 | TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS | YALE UNIVERSITY (US) | 2001-09-07 | — | — | WO | disclosed |
| CN-1305993-A | Cyclic guanyl preparation used as nitrogen oxide synthetic enzyme inhibitor | SEARLE & CO (US) | 2001-08-01 | — | — | CN | disclosed |
| CN-1239952-A | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER (US) | 1999-12-29 | — | — | CN | disclosed |
| CN-1189823-A | Cyclic amidino formulations useful as nitric oxide synthase inhibitors | SEARLE & CO (US) | 1998-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016509-A1 | Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds | COASY, CMA1, ATIC | L3MBTL1 3322/4885GRM5 1400/4885L3MBTL3 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.